PD21-06 MID-TERM RESULTS USING AQUABLATION, AN IMAGE GUIDED ROBOT-ASSISTED WATER JET ABLATION OF THE PROSTATE, FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH).

Abstract

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Surgical Therapy & New Technology I1 Apr 2016PD21-06 MID-TERM RESULTS USING AQUABLATION, AN IMAGE GUIDED ROBOT-ASSISTED WATER JET ABLATION OF THE PROSTATE, FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH). Peter Gilling, Mihir Desai, Paul Anderson, Andrew Tan, and Mahesh Desai Peter GillingPeter Gilling More articles by this author , Mihir DesaiMihir Desai More articles by this author , Paul AndersonPaul Anderson More articles by this author , Andrew TanAndrew Tan More articles by this author , and Mahesh DesaiMahesh Desai More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.1473AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The mid-term results from the multicenter clinical experience of the use of Aquablation to treat lower urinary tract symptoms secondary to BPH are reported. The AquaBeam System is an image-guided robotic system delivering Aquablation, a minimally invasive waterjet therapy for the targeted removal of prostate tissue without the production of heat. Using the real-time transrectal ultrasound image and an integrated conformal planning station, the target region of the prostate is identified and the contour and depth of resection are programmed into the system by the surgeon METHODS Men over 50 years of age with an International Prostate Symptom Score (IPSS) greater than 12, a maximum flow rate of 12 ml/sec, and a prostate volume of 25 – 100 ml were treated using the AquaBeam System (PROCEPT BioRobotics, Redwood Shores, CA). Clinical parameters and safety were assessed out to 1 year after surgery. RESULTS A total of fifty-seven males were enrolled at four centers and treated with Aquablation. The mean age was 69 ± 7 years with a mean prostate size of 48 ± 20 ml and the presence of a median lobe was noted in twenty-six of the fifty-seven (46%) patients. All procedures were technically successful with a mean total operative time of 38 ± 15 minutes and Aquablation resection time of 7 ± 5 minutes. There were no intra-operative complications and adverse events were typically mild and transient. Other peri-operative complications were comparable to those observed with other available BPH therapies. There were no procedure related cases of retrograde ejaculation, urinary incontinence, or erectile dysfunction. At the time of this report, fifty one subjects and thirty three subjects had completed their six-month and one-year follow up, respectively. At six month and one year follow up, statistically significant improvement was observed in IPSS, QoL, Qmax, and PVR. IPSS reduced from 22.9 to 6.8, QoL from 5.0 – 1.6, PVR from 105 – 57 ml, and Qmax improved from 7.8 – 16.7 ml/s from baseline to 12 months. Prostate size reduced to 30 ml at six months. CONCLUSIONS The results of this multicenter experience are promising and Aquablation appears to be safe, feasible, and efficient. The outcomes of this multicenter study support further research in a prospective randomized controlled clinical trial. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e458 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Peter Gilling More articles by this author Mihir Desai More articles by this author Paul Anderson More articles by this author Andrew Tan More articles by this author Mahesh Desai More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...